Resmed
RMD · NYSESurgical & Medical Instruments & Apparatus · Fiscal year ends Jun 30
Resmed reported revenue of $5.7B in the fiscal year ended Jun 2026, up 9.9% from the year before. Operating income was $1.9B, an operating margin of 33.4%, and net income was $1.5B. Operating cash flow of $1.8B less capital expenditure of $156M left free cash flow of $1.6B. It held more cash than debt (net cash $810M).
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Cost of revenue | $1.6B | $1.9B | $2B | $2.1B | $2.2B |
| Gross profit | $2B | $2.4B | $2.7B | $3.1B | $3.5B |
| Research & development | $254M | $288M | $308M | $331M | $378M |
| Selling, general & admin | $738M | $874M | $917M | $993M | $1.1B |
| Operating income | $1B | $1.1B | $1.3B | $1.7B | $1.9B |
| Net interest incomeBanks | −$22M | −$47M | – | – | – |
| Pre-tax income | $960M | $1.1B | $1.3B | $1.7B | $1.9B |
| Income tax | $181M | $204M | $244M | $277M | $396M |
| Net income | $779M | $898M | $1B | $1.4B | $1.5B |
| Diluted EPS | 5.30 | 6.09 | 6.92 | 9.51 | 10.43 |
| Diluted shares | 147M | 147M | 148M | 147M | 146M |
Balance sheet
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | $274M | $228M | $238M | $1.2B | $1.5B |
| Receivables | $576M | $705M | $837M | $939M | $1B |
| Inventory | $744M | $998M | $822M | $928M | $946M |
| Current assets | $1.9B | $2.4B | $2.4B | $3.5B | $4.3B |
| Net PP&E | $498M | $538M | $548M | $551M | $582M |
| Goodwill | $1.9B | $2.8B | $2.8B | $3B | $2.9B |
| Total assets | $5.1B | $6.8B | $6.9B | $8.2B | $9B |
| Payables | $159M | $151M | $238M | $278M | $309M |
| Deferred revenue | $109M | $138M | $153M | $166M | $163M |
| Current liabilities | $689M | $759M | $911M | $1B | $1.4B |
| Short-term debt | $10M | $10M | $10M | $10M | $260M |
| Long-term debt | $765M | $1.4B | $697M | $658M | $399M |
| Total liabilities | $1.7B | $2.6B | $2B | $2.2B | $2.4B |
| Shareholders' equity | $3.4B | $4.1B | $4.9B | $6B | $6.6B |
Cash flow
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Operating cash flow | $351M | $693M | $1.4B | $1.8B | $1.8B |
| Capital expenditure | $135M | $120M | $99M | $90M | $156M |
| Free cash flow | $216M | $574M | $1.3B | $1.7B | $1.6B |
| Depreciation & amortisation | $160M | $165M | $177M | $198M | $201M |
| Stock-based compensation | $65M | $71M | $80M | $92M | $104M |
| Acquisitions | $43M | $1B | $133M | $139M | $351M |
| Share buybacks | $0 | $0 | $150M | $300M | $700M |
| Dividends paid | $245M | $258M | $282M | $311M | $350M |
| Dividend per share | 1.68 | 1.76 | 1.92 | 2.12 | 2.40 |
Key ratios
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 18.0% | 10.9% | 9.8% | 9.9% |
| Operating income growth (YoY) | – | 13.2% | 16.6% | 27.7% | 11.9% |
| EPS growth (YoY) | – | 14.9% | 13.6% | 37.4% | 9.7% |
| Gross margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| Operating margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.4% |
| Net margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| Return on equityBlank when equity is negative | 23.2% | 21.7% | 21.0% | 23.5% | 23.1% |
| ROCEEBIT ÷ (assets − current liabilities) | 22.7% | 18.9% | 22.1% | 23.6% | 24.9% |
| Free cash flow margin | 6.0% | 13.6% | 27.8% | 32.3% | 29.2% |
| Cash conversion (CFO ÷ net income) | 0.45x | 0.77x | 1.37x | 1.25x | 1.19x |
| Receivable days | 59 | 61 | 65 | 67 | 67 |
| Inventory days | 175 | 195 | 148 | 162 | 157 |
| Payable days | 37 | 29 | 43 | 49 | 51 |
| Debt ÷ equity | 0.23x | 0.35x | 0.15x | 0.11x | 0.10x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | $502M | $1.2B | $469M | −$541M | −$810M |
| Current ratio | 2.80x | 3.12x | 2.59x | 3.44x | 3.10x |
Recent filings
More in Surgical & Medical Instruments & Apparatus
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.